Southern Medical Journal. 110(4):300–307, APRIL 2017

DOI: 10.14423/SMJ.0000000000000637

,  

PMID: 28376530

Issn Print: 0038-4348

Publication Date: April 2017


Share this on facebook   Share this on Twitter   Share this on LinkedIn   Email this article  



Print

Autoimmune Neutropenia Updates: Etiology, Pathology, and Treatment

Wais Afzal;Mohamad Owlia;Sarfaraz Hasni;Kam Newman;

+ Author Information


    loading  Checking for direct PDF access through Ovid

Abstract

Autoimmune neutropenia (AIN) is defined as a neutrophil count <1.5 × 109/L caused by increased peripheral destruction of neutrophils from an underlying autoimmune mechanism in which autoantibodies are directed against a patient’s own neutrophils. AIN has a multifactorial etiology ranging from an idiopathic primary phenomenon to secondary disorders associated with established autoimmune diseases. Primary AIN is more prevalent in children, generally self-limited, and typically manifests as a sole hematologic abnormality. Secondary AIN is more common in adults and often occurs in the setting of concurrent autoimmune diseases, infections, malignancies, or medications. It may be seen posttransplantation or occasionally with neurological diseases. Various laboratory modalities are used to detect anti-neutrophil antibodies. Although biologic agents such as rituximab and alemtuzumab (Campath-1H) have been used in the management of AIN, granulocyte colony-stimulating factor remains the first-line therapy. In this article we provide a review of the pathogenesis of AIN, its clinical presentation, and the current treatment options.

Related Topics

    Related Articles

        loading  Loading Related Articles